stockrowHims & Hers Health, Inc.
HIMS Healthcare Drug Manufacturers Specialty & Generic
Hims & Hers Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 59.0% from fiscal 2024.
- Revenue
- +38.3%
- EPS
- −294.7%
- Free cash flow
- +5.09%
- Total debt
- +40.8%
Quarter to June 2026, against a year earlier
Follow HIMS
Alert me
Hims & Hers Health, Inc. (HIMS) Return on equity
Hims & Hers Health, Inc.'s return on equity over the twelve months to 30 June 2026 was −32.0%, down 57.3 percentage points from fiscal 2025 (25.2%). Over the past ten years it has ranged from −114.7% (fiscal 2021) to 30.7% (fiscal 2024); the current reading is higher than 82% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of −0.80% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 25.2% | (5.48) |
| FY2024 | 30.7% | 37.89 |
| FY2023 | −7.18% | 13.14 |
| FY2022 | −20.3% | (20.32) |
| FY2022 | 0.00% | 114.69 |
| FY2021 | −114.7% | (114.69) |
| FY2021 | 0.00% | (25.54) |
| FY2020 | 25.5% | 25.54 |
| FY2020 | 0.00% | 75.36 |
| FY2019 | −75.4% | (75.36) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| LQDA Liquidia Corporation compare | 131.8% |
| LNTH Lantheus Holdings, Inc. compare | 21.8% |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 17.6% |
| RDY Dr. Reddy's Laboratories Ltd compare | 6.60% |
| ALKS Alkermes plc compare | −0.02% |
| HIMS Hims & Hers Health, Inc. | −32.0% |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −74.7% |
| SUPN Indivior Pharmaceuticals Inc. compare | −337.8% |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | −53,107.2% |
| Drug Manufacturers Specialty & Generic industry median | −0.80% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on HIMS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement